Randomized trial · people

Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large placebo-controlled trial, liraglutide 3.0 mg with lifestyle counseling led to more weight loss than counseling alone, with stomach side effects as the most common issue.

Kind
Randomized trial
Studied in
People
Number studied
3731
Published
2015
Journal
N Engl J Med

What they tested

Does a daily 3.0 mg liraglutide shot, added to lifestyle counseling, help adults with excess weight lose more weight than placebo over 56 weeks?

How the study was done

A 56-week randomized, double-blind, placebo-controlled trial in 3731 adults without type 2 diabetes, whose body-mass index (a measure of weight for height) was at least 30, or at least 27 alongside dyslipidemia (high blood fats) or high blood pressure. They were split 2:1 between a daily 3.0 mg liraglutide shot (2487 patients) and placebo, a dummy shot (1244 patients), and both groups also received lifestyle counseling.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking liraglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

By week 56, people on liraglutide had lost a mean of 8.4 kg, while those on placebo had lost 2.8 kg. The gap between groups was -5.6 kg, with a 95% confidence interval (the likely range) running from -6.0 to -5.1. On liraglutide, 63.2% lost at least 5% of their starting weight, compared with 27.1% on placebo, and 33.1% versus 10.6% lost more than 10%. Nausea and diarrhea, mostly mild or moderate, were the most common side effects, and serious events occurred in 6.2% of the liraglutide group versus 5.0% of the placebo group.

What it doesn’t show

The trial ran 56 weeks, so it does not show what happens over longer use or after stopping, and it excluded people with type 2 diabetes. Most patients were women (78.5%), and Novo Nordisk funded the study.

The paper

Pi-Sunyer et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015.

The compound

More studies on Liraglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking liraglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo